Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity

The aim of this study was to investigate pharmacogenetic determinants of skin rash associated with epidermal growth factor receptor (EGFR) inhibitor treatment. A total of 109 prospectively sampled cancer patients, receiving the first treatment with an EGFR inhibitor, were genotyped for functional EG...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The pharmacogenomics journal 2013-04, Vol.13 (2), p.181-188
Hauptverfasser:	Parmar, S, Schumann, C, Rüdiger, S, Boeck, S, Heinemann, V, Kächele, V, Seeringer, A, Paul, T, Seufferlein, T, Stingl, J C
Format:	Artikel
Sprache:	eng
Schlagworte:	631/80/86 631/92/436/434 692/699/1670/122 Analysis Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Biomedical and Life Sciences Biomedicine Cancer Care and treatment Cetuximab Class I Phosphatidylinositol 3-Kinases Epidermal growth factor Epidermal growth factor receptors Erlotinib Hydrochloride Exanthema Exanthema - chemically induced Exanthema - genetics Exanthema - pathology Female Gene Expression Genetic aspects Genetic Association Studies Genetic diversity Haplotypes Human Genetics Humans Male Middle Aged Neoplasms - drug therapy Neoplasms - genetics Neoplasms - pathology Oncology original-article Patients Pharmacogenetics Pharmacotherapy Phosphatidylinositol 3-Kinases - genetics Phosphatidylinositol 3-Kinases - metabolism Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Psychopharmacology Quinazolines - administration & dosage Quinazolines - adverse effects Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Risk factors Skin Skin diseases Survival Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!